13F Holdings
中文EN

ANNX Annexon, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1528115 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.9%
TTM EPS YoY28.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-130.8%
ROA-83.0%
ROIC (approx.)-293.6%
Asset turnover—

Leverage & solvency

Liabilities / assets43.0%
Debt / equity0.35x
Current ratio5.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$184.70M$119.45M$113.76M$112.50M$100.07M
SG&A expense$31.71M$34.62M$29.97M$33.10M$30.65M
Operating income-$216.41M-$154.07M-$143.72M-$145.60M-$130.71M
Pretax income-$206.69M-$138.20M$134.24M$141.95M$130.32M
Income tax$0$0$0$0—
Net income-$206.69M-$138.20M-$134.24M-$141.95M-$130.32M
EBITDA-$214.24M-$151.92M-$141.57M-$143.49M-$128.57M
EPS (basic)-1.34-1.01-1.77-2.60-3.40
EPS (diluted)-1.34-1.01-1.77-2.60-3.40
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)155.11M137.40M75.67M54.67M38.32M
Balance sheet
Cash & equivalents$162.05M$50.53M$226.14M$141.05M$76.01M
Short-term investments$76.29M$262.52M$34.61M$102.64M$167.87M
Current assets$242.19M$316.46M$263.86M$248.10M$247.69M
PP&E, net$10.62M$12.64M$14.77M$16.84M$17.85M
Total assets$277.57M$350.07M$297.67M$285.10M$287.04M
Current liabilities$42.63M$30.51M$17.93M$22.36M$21.74M
Long-term debt$0————
Total debt$0————
Total liabilities$65.92M$56.97M$47.12M$53.90M$55.13M
Shareholders' equity$211.65M$293.11M$250.56M$231.19M$231.91M
Net debt-$162.05M————
Shares outstanding149.36M109.38M78.37M47.72M38.56M
Cash flow statement
Operating cash flow-$186.36M-$118.01M-$121.14M-$116.31M-$106.11M
Capital expenditure$137,000$15,000$193,000$6.53M$1.65M
Free cash flow-$186.49M-$118.02M-$121.33M-$122.83M-$107.76M
Investing cash flow$190.05M-$218.80M$70.70M$58.44M-$88.24M
Financing cash flow$108.86M$161.21M$135.52M$122.91M$1.79M
Depreciation & amortization$2.17M$2.15M$2.15M$2.11M$2.14M
Stock-based compensation$16.42M$19.43M$18.18M$18.52M$16.26M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.